Compare ARK Genomic Revolution ETF (ARKG) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Hims and Hers Health Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Hims and Hers Health Inc trades at $34.02 (market cap $7.96B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | HIMS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $66.18 |
52-Week Low | $23.09 | $14.52 |
Market Cap | — | $7.96B |
Enterprise Value | — | $8.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Hims & Hers Health trades at $34.38, down 3.02% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights expansion in weight-loss therapies and a $400 million JPMorgan facility for financial flexibility, as the stock recovers from earlier regulatory concerns.
The outlook is cautiously optimistic, driven by growth in GLP-1 products and international expansion, but high valuation ratios and projected 2026 losses pose risks. Analyst consensus is a 'Hold' with a $33.57 price target, suggesting limited near-term upside from current levels amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
